Position in OCGN
as of Jun 30, 2026
· filed Aug 13, 2026
Position Value
$5,217,692
-$9,357,060 QoQ
Shares Held
3,410,257
-57.6% QoQ
Ownership
1.01%
of shares outstanding
% of Portfolio
0.01%
of 13F equity value
Holder Rank
#10
of 147 holders
Holding Since
Jun 2021
7 quarters on record
Voting authority
Sole 0%
Shared 100%
None 0%
Common Shares in OCGN Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026MARSHALL WACE, LLP holds $3,055,517,440 across 267 Biotechnology names. OCGN ranks #103 (0.2% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
543,897 | $270,169,956 | |
| 2 | INCY |
Incyte Corp
|
1,310,154 | $148,519,056 | |
| 3 | RPRX |
Royalty Pharma plc
|
2,450,669 | $137,409,009 | |
| 4 | SYRE |
Spyre Therapeutics, Inc.
|
991,693 | $88,042,503 | |
| 5 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
259,799 | $78,207,292 | |
| 6 | TVTX |
Travere Therapeutics, Inc.
|
1,333,207 | $75,739,488 | |
| 7 | MANE |
Veradermics, Inc
|
585,560 | $71,988,746 | |
| 8 | DFTX |
Definium Therapeutics, Inc.
|
1,298,946 | $61,102,419 |
All Filings in OCGN
Export CSV
7 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $5,217,692 | 3,410,257 | Shares | Other | 2026-08-13 | |
| 2026-03-31 | $14,574,752 | 8,052,350 | Shares | Other | 2026-05-15 | |
| 2025-12-31 | $3,416,789 | 2,530,956 | Shares | Other | 2026-02-13 | |
| 2023-03-31 | $32,635 | 38,260 | Shares | Other | 2023-05-15 | |
| 2022-06-30 | $85,086 | 37,483 | Shares | Other | 2022-08-15 | |
| 2022-03-31 | $539,731 | 163,555 | Shares | Other | 2022-05-16 | |
| 2021-06-30 | $1,542,924 | 192,145 | Shares | Sole | 2021-08-13 | |
| No filing history on record for this holder in this stock. | ||||||